home All News open_in_new Full Article

Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company’s Suite of Licenses and Proven U.S. Clinical Trial Supply Experience

TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, welcomes U.S. President Donald Trump’s executive order  to expedite the reclassification of cannabis under the U.S. Controlled Substances Act from Schedule I to Schedule III (the […]


today 4 h. ago attach_file Economics

attach_file Economics
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Technology


ID: 2080084265
Add Watch Country

arrow_drop_down